OpenEvidence
Funding History
| Series A · 02/2025 | $1.0B |
|---|---|
| Series B · 07/2025 | $3.5B |
| Series C · 10/2025 | $6.0B |
| Series D · 01/2026 | $12.0B |
Overview
OpenEvidence builds an AI-powered clinical search and decision-support platform used by doctors at the point of care. Founded in 2022 by Daniel Nadler (previously founder and CEO of Kensho Technologies, a financial-analytics company acquired by S&P Global in 2018) and Zachary Ziegler, a Harvard machine-learning researcher, the company trains medical-domain large language models on peer-reviewed literature and clinical guidelines so physicians can get sourced, evidence-based answers during patient visits. OpenEvidence has struck content partnerships with major medical publishers, including the New England Journal of Medicine, and by January 2026 said it was used by more than 40% of physicians in the United States, with hundreds of millions of cumulative clinical consultations logged on the platform. The company is headquartered in Miami, Florida, and has raised approximately $700 million across four disclosed institutional rounds in under a year, taking its valuation from $1 billion in February 2025 to $12 billion in January 2026.
Private securities are speculative, illiquid, and involve risk of complete loss of principal. You should be prepared to hold private securities for an extended period; there is no assurance of a secondary market, an IPO, or other liquidity event. You are fully responsible for conducting your own due diligence. Pricing is indicative — nothing here is an offer of securities.